Loading stock data…
$1.05-0.03 (-2.78%)
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Lisata Therapeutics, Inc. in the Healthcare sector is trading at $1.05 with a market capitalization of $14M. The stock is currently near its 52-week low of $0.98, remaining 65.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $100,000 | $0↓ | $70,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.99M↑ | -$4.94M↓ | -$3.08M↑ | -$4.41M↑ | -$4.87M |
| Net Income | -$2.93M↑ | -$4.49M↓ | -$2.95M↑ | -$4.25M↑ | -$4.66M |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is i...